Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 9/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | IGF1R | P08069 | 2/20 | 0.42 |
| ▸ | FLT4 | P35916 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6771056 | 0.91 | PLA2G2A (0.44) | PLA2G2AHTR6EGFRIGF1RFLT4 | |
| SCHEMBL6771051 | 0.91 | PLA2G2A (0.44) | PLA2G2AHTR6EGFRIGF1RFLT4 | |
| SCHEMBL29862561 | 0.81 | PLA2G2A (0.59) | PLA2G2AHTR6 | |
| SCHEMBL818539 | 0.81 | PLA2G2A (0.59) | PLA2G2AHTR6 | |
| SCHEMBL817701 | 0.79 | PLA2G2A (0.58) | PLA2G2AHTR6 | |
| SCHEMBL819058 | 0.79 | PLA2G2A (0.61) | PLA2G2AHTR6 | |
| SCHEMBL29862413 | 0.79 | PLA2G2A (0.58) | PLA2G2AHTR6 | |
| Water SCHEMBL6975765 | 0.79 | PLA2G2A (0.60) | PLA2G2AHTR6 | |
| Water SCHEMBL6981285 | 0.79 | PLA2G2A (0.57) | PLA2G2AHTR6 | |
| SCHEMBL6699402 | 0.78 | HTR6 (0.71) | PLA2G2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040204473-A1 | Substituted tricyclics | LIN HO-SHEN (US) | 2004-10-14 | — | — | US | disclosed |
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| EP-0839806-B1 | Substituted tricyclics | LILLY CO ELI (US) | 2003-07-09 | — | — | EP | disclosed |
| US-20030096854-A1 | Substituted tricyclics | ELI LILLY AND COMPANY | 2003-05-22 | — | — | US | disclosed |
| EP-1248769-A2 | CARBAZOLE DERIVATIVES AS INHIBITORS OF SPLA2 | ELI LILLY AND COMPANY (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001049662-A2 | CARBAZOLE DERIVATIVES AS INHIBITORS OF SPLA2 | ELI LILLY AND COMPANY (US) | 2001-07-12 | — | — | WO | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |
| EP-0839806-A1 | Substituted tricyclics | ELI LILLY AND COMPANY (US) | 1998-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096854-A1 | Substituted tricyclics | LITAF, PLA2G4A, LTC4S | PLA2G2A 34/4885HTR6 475/4885EGFR 4878/4885 |
| US-20040204473-A1 | Substituted tricyclics | PLA2G4A, PLAA, LTC4S | PLA2G2A 28/4885HTR6 376/4885EGFR 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.